Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSP3 Biofusion
- Development stage
- Unknown
- Lead developer
- Vac4All
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
MSP3 Biofusion is a second-generation malaria vaccine developed by Vac4All, designed to target the Merozoite Surface Protein 3 (MSP3) antigen on Plasmodium falciparum parasites during the blood stage of infection. As part of the ADAMVAX (antibody-dependent anti-malaria vaccines) platform, this biofusion protein vaccine is engineered to be 20-100 fold more potent at inducing correlates of protection compared to the first-generation MSP3-LSP vaccine. It works by eliciting antibodies that target the asexual, disease-causing stages of the parasite, providing protection against clinical malaria. The vaccine is currently in Phase 1/2b clinical development.
- Other names
- MSP3-BiofusionMSP-3-BiofusionMSP 3-BiofusionVac4All-MSP3Vac-4All-MSP3Vac 4All-MSP3
02
Targets
Beyond the preview
Go deeper on MSP3 Biofusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSP3 Biofusion.